地舒单抗停药后血清CTX-I反弹模式及唑来膦酸救援的真实世界分析
该回顾性研究纳入65例(30例绝经后骨质疏松、35例癌症治疗相关骨丢失)在地舒单抗末次给药6个月后接受单次5 mg唑来膦酸输注的女性,采用线性混合效应模型拟合s-CTX-I轨迹。结果显示s-CTX-I呈非线性升高,于唑来膦酸后6–9个月达峰、12个月部分回落,两组轨迹无交互(p>0.3),仅发生1例椎体骨折;反弹幅度与地舒单抗治疗期间腰椎、股骨颈或全髋BMD增幅无关。
要点
- 地舒单抗停药后s-CTX-I呈非线性反弹,唑来膦酸后6–9个月达峰,12个月部分回落。
- 绝经后骨质疏松与癌症治疗相关骨丢失两组反弹轨迹无显著交互(p>0.3)。
- 反弹幅度与地舒单抗治疗期间腰椎、股骨颈或全髋BMD增幅无关。
核心结论
- 真实世界实践中,地舒单抗停药后骨吸收呈可重复的非线性反弹,即使给予唑来膦酸救援仍仅部分缓解。
- 反弹峰值s-CTX-I仍低于绝经前女性参考上限,且反弹幅度与既往密度治疗反应无关。
- 绝经后骨质疏松与癌症治疗相关骨丢失反弹模式相似,提示共享生物学机制,支持个体化、基于骨转换标志物的监测策略而非固定时间策略。
研究设计与样本
- 回顾性分析65例女性(30例绝经后骨质疏松,35例癌症治疗相关骨丢失),均在地舒单抗停药6个月后接受单次5 mg唑来膦酸输注。
- s-CTX-I测量时间范围为相对唑来膦酸-30至+360天,采用含自然三次样条(节点0、180天)的线性混合效应回归建模,并校正年龄与地舒单抗使用时长。
主要发现
- s-CTX-I呈非线性升高,于唑来膦酸后6–9个月达峰,12个月时达部分平台期。
- 样条模型拟合显著优于线性模型(ΔAIC > 20)。
- 时间与适应症(绝经后骨质疏松 vs 癌症治疗相关骨丢失)无交互作用(p > 0.3),提示两组反弹轨迹可比。
- 峰值s-CTX-I值仍低于绝经前女性参考上限。
- 反弹强度(Δs-CTX-I)与地舒单抗治疗期间腰椎、股骨颈或全髋BMD百分比增幅无关;随访期间仅发生1例椎体骨折。
关键数值与推荐
- 唑来膦酸救援方案:地舒单抗停药6个月后单次5 mg静脉输注。
- s-CTX-I反弹峰值时间:唑来膦酸后6–9个月;12个月部分回落。
- 模型比较:样条模型优于线性模型(ΔAIC > 20);时间×适应症交互p > 0.3。
临床怎么用
- 地舒单抗停药后即使给予唑来膦酸救援,仍需关注6–9个月的骨吸收反弹窗口。
- 反弹幅度与既往BMD反应无关,不宜仅依据密度变化预判反弹强度。
- 可考虑基于骨转换标志物的个体化监测,而非固定时间策略。
局限性
- 回顾性设计,样本量65例。
- 仅发生1例椎体骨折,骨折结局信息有限。
- s-CTX-I测量时间范围为相对唑来膦酸-30至+360天。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Stopping denosumab causes a temporary rebound in bone resorption, even when zoledronate is administered afterwards. We analyzed 65 women with postmenopausal osteoporosis or cancer treatment-induced bone loss who received a single zoledronate infusion 6 months after their last denosumab dose. Blood levels of the bone turnover marker CTX were modeled over time, showing a nonlinear increase peaking between 6 and 9 months and partially declining by 12 months. The rebound pattern was comparable in both groups, and only one vertebral fracture occurred. These findings show that the rebound is only partially mitigated by zoledronate. BACKGROUND: Denosumab (Dmab) discontinuation triggers a rebound in bone resorption that may be only partially mitigated by zoledronate (ZOL). However, the temporal pattern of this rebound under real-world conditions remains poorly defined. We aimed to model continuous serum C-terminal telopeptide of type I collagen (s-CTX-I) trajectories after Dmab withdrawal and ZOL rescue and to compare rebound profiles between postmenopausal osteoporosis (PMO) and cancer treatment-induced bone loss (CTIBL). METHODS: Sixty-five women who received a single 5-mg ZOL infusion 6 months after Dmab discontinuation were retrospectively analyzed (30 PMO, 35 CTIBL). s-CTX-I measurements obtained from -30 to +360 days relative to ZOL were modeled with linear mixed-effects regression using natural cubic splines (knots 0, 180 days), adjusting for age and Dmab duration. RESULTS: s-CTX-I increased nonlinearly, peaking at 6-9 months post-ZOL and reaching a partial plateau by 12 months. The spline model fits the data substantially better than a linear specification (ΔAIC > 20). No interaction was found between time and indication (PMO vs CTIBL; p > 0.3), indicating comparable rebound trajectories across groups. Peak s-CTX-I values remained below the upper reference limit for premenopausal women. Rebound intensity (Δs-CTX-I) was not associated with percentage bone mineral density (BMD) gain at the lumbar spine, femoral neck, or total hip during Dmab therapy. Only one vertebral fracture occurred during follow-up. CONCLUSIONS: In real-world practice, bone resorption rebounds after Dmab discontinuation in a reproducible, nonlinear pattern despite ZOL rescue, peaking around 6-9 months. Although peak s-CTX-I values remained within the premenopausal reference range, rebound magnitude was unrelated to prior densitometric response, supporting a biologically driven reactivation of remodeling. The similarity between PMO and CTIBL suggests a shared biological mechanism and supports individualized, turnover-guided monitoring rather than fixed-timing strategies.
引用
- Aldegheri F, Fassio A, Appoloni M, et al. Real-world rebound pattern of serum collagen type I C-telopeptide after denosumab discontinuation and zoledronate rescue in postmenopausal osteoporosis and cancer treatment-induced bone loss. Osteoporos Int. 2026. PMID: 41790191. doi:10.1007/s00198-026-07936-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。